Atopic Dermatitis patient


We are leading the science in immunology through our research and development of advanced treatments for chronic, difficult to treat inflammatory diseases.

With two treatments on the market and a robust pipeline, Immunology is a strong area of growth for us and one in which have already made a significant impact on the lives of patients. In collaboration with Regeneron, we launched a first in class treatment for adults and adolescents with moderate-to-severe atopic dermatitis and adults and adolescents with moderate-to-severe asthma, two chronic and difficult to treat diseases driven by underlying inflammation. Our second treatment is for adults with moderate to severe rheumatoid arthritis (RA), a chronic and painful inflammatory disorder that damages the joints. Our pipeline includes other allergic and respiratory diseases, including nasal polyposis, eosinophilic esophagitis, COPD, and food allergies, as well as programs focused on juvenile idiopathic arthritis, giant cell arteritis, and polymyalgia rheumatic.

Above from left to right: Gerard, rheumatoid arthritis, France; Miwako, atopic dermatitis, Japan; Jeff, asthma, Canada

Understand AD logo

Atopic dermatitis: From education to empowerment

Understand AD is a national awareness campaign focused on educating people about moderate-to-severe atopic dermatitis (AD), a chronic form of eczema that can be serious. By educating Americans about the physical and quality of life impact of atopic dermatitis, Understand AD will give a voice to and empower the people living with the disease.